(Q38108248)

29 August 2017

title

The adolescent and young adult with cancer: state of the art -- bone tumors (English)

1 reference

29 August 2017

1 reference

Nino Rainusso

1

1 reference

29 August 2017

Lisa L Wang

series ordinal

2

1 reference

29 August 2017

Jason T Yustein

series ordinal

3

1 reference

29 August 2017

publication date

1 August 2013

1 reference

29 August 2017

published in

Current Oncology Reports

1 reference

29 August 2017

volume

15

1 reference

29 August 2017

issue

4

1 reference

29 August 2017

page(s)

296-307

1 reference

Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

The genetics of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Notch signaling contributes to the pathogenesis of human osteosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Critical role of notch signaling in osteosarcoma invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Biology and therapeutic advances for pediatric osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

International collaboration is feasible in trials for rare conditions: the EURAMOS experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Addition of pamidronate to chemotherapy for the treatment of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

The increasing complexity of the cancer stem cell paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

The Biology of Ewing sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing's family tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Oncogenic fusion protein EWS/FLI1 down-regulates gene expression by both transcriptional and posttranscriptional mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Diagnostic accuracy of ¹⁸F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Treatment of Ewing sarcoma family of tumors: current status and outlook for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Second cancers in patients with the Ewing sarcoma family of tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Role of radiotherapy in Ewing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors. Toxicity analysis and treatment results of the EICESS-92 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Ewing's sarcoma: standard and experimental treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Nutlin-3a is a potential therapeutic for ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

NVP-BEZ235 as a new therapeutic option for sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0321-9

Current therapeutic approaches in metastatic and recurrent ewing sarcoma

21 January 2018

1 reference

12 December 2020

Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: an Intergroup Study

1 reference

12 December 2020

Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement

1 reference

12 December 2020

Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999

1 reference

12 December 2020

Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols

1 reference

12 December 2020

The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma

1 reference

12 December 2020

Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas

1 reference

12 December 2020

Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients

1 reference

12 December 2020

Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group

1 reference

12 December 2020

Is Ewing's sarcoma a stem cell tumor?

1 reference

12 December 2020

Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.

1 reference

12 December 2020

Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience

1 reference

12 December 2020

Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital

1 reference

12 December 2020

Experimental evidence for a neural origin of Ewing's sarcoma of bone

1 reference

12 December 2020

Targeting the p53 Pathway in Ewing Sarcoma.

1 reference

12 December 2020

Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution

1 reference

12 December 2020

10.1007/S11912-013-0321-9

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1050579506

0 references

1 reference